Dr. Marlana Orloff, MD
Claim this profileThomas Jefferson University
Studies Eye Cancer
Studies Uveal Melanoma
10 reported clinical trials
19 drugs studied
Area of expertise
1Eye Cancer
Stage IV
HLA-A negative
GNAQ positive
2Uveal Melanoma
Stage IV
HLA-A negative
GNAQ positive
Affiliated Hospitals
Clinical Trials Marlana Orloff, MD is currently running
Darovasertib + Crizotinib
for Uveal Melanoma
This trial is testing a new drug combination (IDE196 and crizotinib) on patients with a specific type of eye cancer that has spread. The goal is to see if this combination can stop or slow down the cancer better than other treatments. Crizotinib has been used in treating various cancers with ALK gene rearrangements, showing high response rates.
Recruiting1 award Phase 2 & 38 criteria
IDE196 Combinations
for Solid Tumors
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors. Phase 1 (dose escalation - monotherapy) will assess safety, tolerability and pharmacokinetics of IDE196 via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 (dose escalation - binimetib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and binimetinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 (dose escalation - crizotinib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and crizotinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Evaluation of safety and efficacy across multiple doses may be explored in the dose optimization part of the study. Crizotinib monotherapy with crossover to combination cohort may be assessed for safety and to show the contribution of each study drug to anti-tumor activity. As of Protocol Amendment 10, Phase 1, Phase 2 dose expansion in IDE196 monotherapy, and Phase 2 dose expansion of IDE196 in combination with binimetinib have been fully enrolled. There were no patients enrolled in the crizotinib monotherapy cohorts.
Recruiting1 award Phase 1 & 29 criteria
More about Marlana Orloff, MD
Clinical Trial Related2 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Marlana Orloff, MD has experience with
- Pembrolizumab
- IDE196
- Crizotinib
- Ipilimumab
- Nivolumab
- SD-101
Breakdown of trials Marlana Orloff, MD has run
Eye Cancer
Uveal Melanoma
Melanoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Marlana Orloff, MD specialize in?
Marlana Orloff, MD focuses on Eye Cancer and Uveal Melanoma. In particular, much of their work with Eye Cancer has involved Stage IV patients, or patients who are HLA-A negative.
Is Marlana Orloff, MD currently recruiting for clinical trials?
Yes, Marlana Orloff, MD is currently recruiting for 4 clinical trials in Philadelphia Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Marlana Orloff, MD has studied deeply?
Yes, Marlana Orloff, MD has studied treatments such as Pembrolizumab, IDE196, Crizotinib.
What is the best way to schedule an appointment with Marlana Orloff, MD?
Apply for one of the trials that Marlana Orloff, MD is conducting.
What is the office address of Marlana Orloff, MD?
The office of Marlana Orloff, MD is located at: Thomas Jefferson University, Philadelphia, Pennsylvania 19107 United States. This is the address for their practice at the Thomas Jefferson University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.